CLINICAL NEWS
The researchers also tested whether these
models could accurately predict the probability
of survival and mortality during induction therapy, first complete remission, and after relapse.
“The resulting personalized predictions
provide a quantitative risk assessment and allow evaluating the effect of treatment decisions
such as allogeneic hematopoietic cell transplantation versus standard chemotherapy in first
complete remission,” the authors concluded.
for multiple co-occurring factors.
Overall, about two-thirds of predicted interpatient risk variation was related to genomic
factors (i.e., balanced rearrangements, copy
number changes, and point mutations). The remaining one-third could be attributed primarily
to demographic variables, treatment, and diagnostic blood counts. “A large share, but not all,
prognostic information seems to be determined
by genomic factors,” the authors wrote.
This study acts as proof of principle of this
prediction framework but, before the framework could be used as a clinical decision support tool, it needs to be tested in larger cohorts
of AML patients prospectively. ●
REFERENCE
Gerstung M, Papaemmanuil E, Martincorena I, et al. Personally tailored risk
prediction of AML based on comprehensive genomic and clinical data. Abstract
#85. Presented at the American Society of Hematology’s Annual Meeting,
December 5, 2015; Orlando, FL.
T:7”
Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*
All Adverse Reactionsa
Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*
Grade 3/4 Adverse
Reactionsb
Grade 3/4 Adverse
Reactionsb
All Adverse Reactionsa
Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)
Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)
Musculoskeletal and connective tissue disorders
Psychiatric disorders
Back painc
170 ( 32) 145 (26.9) 116 (21.4)
37 (7)
34 (6.3)
28 (5.2)
Muscle spasms f
109 (20.5) 102 (18.9) 61 (11.3)
< 1%
< 1%
< 1%
Arthralgia f
101 (19.0) 71 (13.1) 66 (12.2)
9 (1.7)
8 (1.5)
8 (1.5)
Bone pain f
87 (16.4) 77 (14.3) 62 (11.5) 16 (3.0)
15 (2.8)
14 (2.6)
Pain in extremity f 79 (14.8) 66 (12.2) 61 (11.3)
8 (1.5)
8 (1.5)
7 (1.3)
Musculoskeletal
pain f
67 (12.6) 59 (10.9)
36 (6.7)
< 1%
< 1%
< 1%
Musculoskeletal
chest pain f
60 (11.3)
51 (9.4)
39 (7.2)
6 (1.1)
< 1%
< 1%
Muscular
weakness f
43 (8.1)
35 (6.5)
29 (5.4)
< 1%
8 (1.5)
< 1%
40 (7.5)
19 (3.5)
10 (1.8)
< 1%
< 1%
< 1%